Lipocine (NASDAQ:LPCN) Director John Higuchi Acquires 12,561 Shares of Company Stock

Lipocine Inc. (NASDAQ:LPCN) Director John Higuchi acquired 12,561 shares of Lipocine stock in a transaction on Monday, September 28th. The stock was acquired at an average price of $2.16 per share, with a total value of $27,131.76. Following the purchase, the director directly owned 216,358 shares in the company, valued at approximately $467,333.28. This trade represents a 6.16% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Lipocine Trading Up 1.9%

Shares of NASDAQ:LPCN traded up $0.04 during midday trading on Wednesday, reaching $2.20. The company had a trading volume of 31,369 shares, compared to its average volume of 33,043. The stock has a market cap of $18.13 million, a P/E ratio of -1.23 and a beta of 0.47. The company’s 50 day moving average price is $2.17 and its 200 day moving average price is $2.77. Lipocine Inc. has a 52-week low of $1.81 and a 52-week high of $12.37.

Lipocine (NASDAQ:LPCN) last posted its quarterly earnings data on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.08. The business had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.21 million. Lipocine had a negative net margin of 755.39% and a negative return on equity of 64.75%. Research analysts forecast that Lipocine Inc. will post -1.54 EPS for the current fiscal year.

Hedge Funds Weigh In On Lipocine

Several large investors have recently modified their holdings of LPCN. Dimensional Fund Advisors LP raised its position in shares of Lipocine by 57.5% in the first quarter. Dimensional Fund Advisors LP now owns 19,122 shares of the specialty pharmaceutical company’s stock valued at $153,000 after purchasing an additional 6,982 shares during the period. ADAR1 Capital Management LLC bought a new position in Lipocine in the 1st quarter worth approximately $185,000. Exome Asset Management LLC bought a new position in Lipocine in the 1st quarter worth approximately $486,000. Persistent Asset Partners Ltd purchased a new position in Lipocine in the 4th quarter valued at approximately $567,000. Finally, Seven Fleet Capital Management LP purchased a new position in Lipocine in the 1st quarter valued at approximately $998,000. Hedge funds and other institutional investors own 9.11% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. HC Wainwright reaffirmed a “neutral” rating and issued a $4.00 price target on shares of Lipocine in a report on Monday, September 21st. Wall Street Zen raised Lipocine from a “sell” rating to a “hold” rating in a report on Saturday, July 18th. Cantor Fitzgerald reissued an “overweight” rating on shares of Lipocine in a research report on Tuesday, September 22nd. Finally, Weiss Ratings upgraded Lipocine from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 24th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $4.00.

Lipocine Company Profile

Lipocine Inc is a clinical-stage biopharmaceutical company based in Salt Lake City, Utah, focused on developing oral therapies for conditions that have traditionally been treated with injections or other less convenient formulations. The company uses its proprietary Lip’ral drug-delivery technology to improve the absorption and administration of certain active pharmaceutical ingredients.

Lipocine’s lead product, TLANDO (testosterone undecanoate), is an oral testosterone-replacement therapy approved by the U.S.